317 related articles for article (PubMed ID: 32926353)
1. Bulevirtide: First Approval.
Kang C; Syed YY
Drugs; 2020 Oct; 80(15):1601-1605. PubMed ID: 32926353
[TBL] [Abstract][Full Text] [Related]
2. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
3. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
4. HBV/HDV Coinfection: A Challenge for Therapeutics.
Koh C; Da BL; Glenn JS
Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
[TBL] [Abstract][Full Text] [Related]
5. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
[TBL] [Abstract][Full Text] [Related]
6. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Wedemeyer H; Schöneweis K; Bogomolov P; Blank A; Voronkova N; Stepanova T; Sagalova O; Chulanov V; Osipenko M; Morozov V; Geyvandova N; Sleptsova S; Bakulin IG; Khaertynova I; Rusanova M; Pathil A; Merle U; Bremer B; Allweiss L; Lempp FA; Port K; Haag M; Schwab M; Zur Wiesch JS; Cornberg M; Haefeli WE; Dandri M; Alexandrov A; Urban S
Lancet Infect Dis; 2023 Jan; 23(1):117-129. PubMed ID: 36113537
[TBL] [Abstract][Full Text] [Related]
8. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.
Sandmann L; Wedemeyer H
Clin Liver Dis; 2021 Nov; 25(4):831-839. PubMed ID: 34593156
[TBL] [Abstract][Full Text] [Related]
9. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients.
Sandmann L; Deterding K; Bremer B; Port K; Cornberg M; Wedemeyer H; Maasoumy B
J Viral Hepat; 2023 Apr; 30(4):283-286. PubMed ID: 36648369
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
Ferrante ND; Lo Re V
Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
[TBL] [Abstract][Full Text] [Related]
12. [Bulevirtide as the first specific agent against hepatitis D virus infections-mechanism and clinical effect].
Nkongolo S; Hollnberger J; Urban S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Feb; 65(2):254-263. PubMed ID: 35028672
[TBL] [Abstract][Full Text] [Related]
13. Bulevirtide and emerging drugs for the treatment of hepatitis D.
Xu HY; Yang JO; Chen PH; Han SB
Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
[TBL] [Abstract][Full Text] [Related]
14. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
Cornberg M; Lok AS; Terrault NA; Zoulim F;
J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
[TBL] [Abstract][Full Text] [Related]
15. Chronic hepatitis delta: A state-of-the-art review and new therapies.
Gilman C; Heller T; Koh C
World J Gastroenterol; 2019 Aug; 25(32):4580-4597. PubMed ID: 31528088
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs in development for Hepatitis D.
Rizzetto M
Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
[TBL] [Abstract][Full Text] [Related]
17. Bulevirtide for HBV and HDV infections.
Yardeni D; Koh C
Drugs Today (Barc); 2021 Jul; 57(7):433-448. PubMed ID: 34268531
[TBL] [Abstract][Full Text] [Related]
18. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
19. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies.
Zhang Z; Urban S
J Hepatol; 2021 Mar; 74(3):686-699. PubMed ID: 33276031
[TBL] [Abstract][Full Text] [Related]
20. Chronic hepatitis D-What is changing?
Yardeni D; Heller T; Koh C
J Viral Hepat; 2022 Apr; 29(4):240-251. PubMed ID: 35122369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
